

Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024

<https://marketpublishers.com/r/GAD5A8EA37EEN.html>

Date: March 2018

Pages: 255

Price: US\$ 2,600.00 (Single User License)

ID: GAD5A8EA37EEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024” Report Highlight:

Role of Dendritic Cells in Immune System & Cancer

Price & Dosage Analysis of Marketed Dendritic Cell Cancer Vaccine

Availability & Efficacy Analysis

Marketed Dendritic Cell Cancer Vaccines Clinical Insight: 3 Vaccines

Comparative Assessment of Provenge v/s other Key Therapeutics

Dendritic Cell Cancer Vaccines Clinical Pipeline by Company, Indication & Phase: 63 Vaccines

Conventional therapies like surgery, radiotherapy and chemotherapies are the initial approaches for treating cancer. However, several researchers indicated that these conventional therapies are unable to treat cancer from its root cause and also produce many adverse effects thus, cannot be considered as a future of cancer therapy. Further findings demonstrated that cancer cells directly affect T-cells of the immune system and suppresses the immune activity against it resulting in uninhibited growth of cancer cells. Such incidences triggered the era of modern cancer therapy.

Advances in cellular technologies initiated the research towards exploitation of immune cells for the development of advanced vaccines for treating cancer. One of the cells which are found to be the most attractive target for developing therapeutic vaccines are Dendritic cells as they have the ability to present multiple antigens which are most suited to be a therapy for a multi-cause disease like cancer.

Dendritic cell cancer vaccines have gained significant importance in the market with the approval of first dendritic cell cancer vaccine for metastatic prostate cancer called Provenge. Provenge was approved almost a decade ago and has generated high revenues for the pharmaceutical companies. Dendritic cell vaccines became one of the most promising approaches as it works by boosting up the immune system which in turn will cause no or minimal side effects. Furthermore, cancer is disease with multiple causes and risk factors; researchers stated that instead of preventive vaccines, effective therapeutic vaccines can be developed to treat cancer.

Followed by the approval of Provenge, several similar products were developed for other indications in different regions of the world including CreaVax in South Korea for prostate and kidney cancer and Apceden in India for multiple solid tumors. Additionally, a wide range of dendritic cell vaccines entered in different phases of clinical pipeline such as Vaccell in Japan, TAP Cells in Chile, MelCancerVac in North America and Rocapuldencel-T in US etc. All these dendritic cell cancer vaccines are expected to be approved and commercialized and enhance the Global Dendritic cell vaccine market.

Dendritic cell vaccine is the fastest growing segment of cancer vaccine market with other classes of vaccine like peptide vaccines, HPV vaccine, HBV vaccines etc. Dendritic cell vaccines are more specific for treating cancer while others are limited to the treatment of chronic conditions which can cause cancer. Additionally, development of dendritic cell vaccine has been one of the fastest growing sectors amongst all and has resulted in a strong clinical pipeline with more than 60 products in different phases of clinical trials.

Moreover dendritic cell vaccines are unique of its kind which is specifically approved for advanced stages of cancer. Lack of availability of targeted therapies for advance stage of diseases, highly unmet medical needs of metastatic cancer patients indicates exponential rise in the demand for dendritic cell cancer vaccines. Furthermore, commercial successes of Provenge which is available in more than 35 countries; CreaVax in South Korea due to large target patient base has resulted in significant growth of the market.

Increasing prevalence of cancer around the globe will fuel the commercial success of unique dendritic cell vaccines. For instance, in 2018 more than 70000 and 120000 people are expected to be affected by renal cell carcinoma in US and Europe respectively which will result in great market success of Rocapuldencel-T in the coming future. Additionally, nearly 1 Million new incidences of cancer are expected to occur in Japan in 2018 which will fuel the dendritic cell cancer vaccine market in this region.

Moreover, dendritic cell vaccines are considered to be the future of cancer therapy. With the advancement in technology and better understanding of cancer cells, dendritic cells can be used as a preventive measure in the coming future. Additionally, dendritic cell cancer vaccines are one of the safest methods to treat cancer as they boost patient's own immune system by presenting and activating specific antigens at the tumor site. Additionally, presence of a wide range of antigens in human immune system and cancer cells provides opportunities for the development of a wide range of unique products.

Contents

1. PROLOGUE TO DENDRITIC CELL CANCER VACCINE

- 1.1 Historical Overview of Dendritic Cell Cancer Vaccine
- 1.2 Dendritic Cell Vaccines: A Revolutionary Cancer Therapy

2. ROLE OF DENDRITIC CELLS IN IMMUNE SYSTEM & CANCER

- 2.1 Dendritic Cell: Integral Part of Human Immune System
- 2.2 Effects of Cancer on Dendritic Cell Mediated Immunity

3. MECHANISM OF ACTION OF DENDRITIC CELL CANCER VACCINES

- 3.1 Process Involved in Manufacturing Dendritic Cell Vaccine
- 3.2 Understanding Working Mechanism of Dendritic Cell Vaccine against Cancer Cells

4. COMMERCIALLY APPROVED DENDRITIC CELL CANCER VACCINE: EFFICACY, AVAILABILITY, PRICE & DOSAGE ANALYSIS

- 4.1 Provenge
 - 4.1.1 Clinical Efficacy
 - 4.1.2 Availability, Dosage & Treatment Schedule
 - 4.1.3 Treatment Cost Analysis
 - 4.1.4 Manufacturing Cost & Market Worth
- 4.2 Apceden (Apceden-L, Apceden-O, Apceden-C, Apceden-P)
 - 4.2.1 Clinical Efficacy
 - 4.2.2 Availability, Dosage & Treatment Schedule
- 4.3 CreaVax RCC
 - 4.3.1 Availability, Dosage & Treatment Schedule
 - 4.3.2 Manufacturing Cost Process & Involved Technologies

5. MARKETED DENDRITIC CELL CANCER VACCINES CLINICAL INSIGHT

- 5.1 Sipuleucel-T (Provenge)
- 5.2 Dendritic Cell Vaccine (CreaVax-HCC, CreaVax-PC & CreaVax-RCC)
- 5.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

6. PROMISING CANDIDATES IN DENDRITIC CELL CANCER VACCINE IN

CLINICAL PIPELINE

- 6.1 CreaVax-HCC, CreavAX-PC, CreaVax-BC
- 6.2 Rocapuldencel-T
- 6.3 MelCancerVac
- 6.4 Apceden (Apceden-GBM, Apceden-RCC)
- 6.5 Vaccell

7. COMPARATIVE ASSESSMENT OF PROVENGE V/S OTHER THERAPEUTICS FOR PROSTATE CANCER

- 7.1 Provenge v/s Jevtana
 - 7.1.1 Clinical Efficacy
 - 7.1.2 Treatment Course & Dosage
 - 7.1.3 Therapy Price Analysis
- 7.2 Provenge v/s Zytiga
 - 7.2.1 Clinical Efficacy
 - 7.2.2 Treatment Course & Dosage
 - 7.2.3 Therapy Price Analysis

8. DENDRITIC CELL CANCER VACCINE MARKET OPPORTUNITY REGIONAL ANALYSIS

- 8.1 North America
- 8.2 India
- 8.3 South Korea
- 8.4 Japan

9. DENDRITIC CELL CANCER VACCINE COMBINATION THERAPY WITH OTHER CANCER THERAPIES

- 9.1 Dendritic Cell Cancer Vaccine with Radiotherapy
- 9.2 Dendritic Cell Cancer Vaccine with Monoclonal Antibodies

10. GLOBAL DENDRITIC CELL CANCER VACCINE CURRENT MARKET OVERVIEW

- 10.1 Global Dendritic Cell Cancer Vaccine Market Trends
- 10.2 Global Dendritic Cell Vaccine Market Regional Insight

10.2.1 Scope of Dendritic Cell Vaccine Market by Ongoing Researches & Available Advanced Therapies by Region

10.2.2 Scope of Dendritic Cell Vaccine Market by Investments for from Different Sectors

10.2.3 Scope of Reimbursement of Dendritic Cell Cancer Therapy

11. PROMISING FUTURE OF DENDRITIC CELL VACCINES IN VARIOUS CANCER

11.1 Dendritic Cell Vaccine in Stage-III Melanoma

11.2 Dendritic Cell Vaccine in Acute Myeloid Leukemia

11.3 Dendritic Cell Vaccine in Brain Tumor

12. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET DYNAMICS

12.1 Favorable Market Parameters

12.2 Market Growth Challenges

13. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET FUTURE FORECAST

13.1 Technical Advancements in Dendritic Cell Cancer Vaccine in Future

13.2 Increase in Prevalence of Cancer Providing a Large Target Patient Base for Dendritic Cell Cancer Vaccine in Future

14. GLOBAL DENDRITIC CELL CANCER VACCINES CLINICAL PIPELINE OVERVIEW

15. GLOBAL DENDRITIC CELL CANCER VACCINES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

15.1 Unknown

15.2 Research

15.3 Preclinical

15.4 Clinical

15.5 Phase-I

15.6 Phase-I/II

15.7 Phase-II

15.8 Phase-II/III

15.9 Phase-III

16. COMPETITIVE LANDSCAPE

- 16.1 3M Company
- 16.2 Activartis
- 16.3 Argos Therapeutics
- 16.4 Batavia Bioservices
- 16.5 Bellicum Pharmaceuticals
- 16.6 Creagene
- 16.7 DanDrit Biotech
- 16.8 DCPrime
- 16.9 Dendreon Corporation
- 16.10 Elios Therapeutics
- 16.11 ImmunoCellular Therapeutics
- 16.12 Immunicum
- 16.13 Kiromic
- 16.14 Medigene
- 16.15 Merck
- 16.16 Northwest Biotherapeutics
- 16.17 Glaxo Smith Kline
- 16.18 ImmunoCellular Therapeutics
- 16.19 SOTIO
- 16.20 Tella Incorporation
- 16.21 Theravectys
- 16.22 Vaxil BioTherapeutics

List Of Figures

LIST OF FIGURES

Figure 1-1: Milestones in the History of Dendritic Cell Cancer Vaccine Development

Figure 2-1: Dendritic Cell in Human Immune System

Figure 2-2: Effects of Tumor Cell in Dendritic Cell Dysfunction Leading to Tumor Progression

Figure 3-1: Process of Harvesting Dendritic Cell to Develop Vaccines

Figure 3-2: General Mechanism of Action of Dendritic Cell Vaccine

Figure 4-1: Provenge: Efficacy on the Basis of Clinical Trials

Figure 4-2: Provenge – Number of Autologous CD54+ Activated Cells (Million)

Figure 4-3: Provenge – Dosage Administration (Minutes)

Figure 4-4: Provenge - Average Duration of Therapy

Figure 4-5: Provenge - Therapy Cost Analysis (US\$/Infusion), 2018

Figure 4-6: Provenge – Average Cost (US\$/Patient), 2018

Figure 4-7: Provenge – Therapy Cost Analysis (US\$/Treatment Course), 2018

Figure 4-8: Provenge – Company's Expenditure in Drug Development & Therapy Market Value (US\$ Billion)

Figure 4-9: Apceden – Median Progression-Free Survival in Patients with Solid Tumors (Number of Months), 2018

Figure 4-10: Apceden – Median Progression Free Survival in Patients with Progressive Solid Tumors (Number of Months), 2018

Figure 4-11: Apceden v/s Provenge – Adverse Side Effects (%), 2018

Figure 4-12: Apceden – Availability of Vial & Vials Required in Apceden Therapy, 2018

Figure 4-13: Apceden – Intervals Between Multiple Doses of Treatment

Figure 4-14: CreaVax RCC – Approval Analysis by Phase (Year)

Figure 4-15: CreaVax RCC – Treatment Course Duration (Weeks), 2018

Figure 4-16: CreaVax RCC – Vial Composition Analysis (mL/Dose & Number of Cells/Dose), 2018

Figure 4-17: South Korea - CreaVax RCC Patent Cost (US\$)

Figure 4-18: South Korea – Pharmaceutical Compositions comprising Dendritic Cell Patent Cost (US\$)

Figure 7-1: Provenge v/s Jevtana – Median Progression Free Survival (Months)

Figure 7-2: Provenge v/s Jevtana – Overall Survival (Months)

Figure 7-3: Provenge v/s Jevtana – Discontinuation of Treatment in Patients due to Adverse Effects (%)

Figure 7-4: Provenge v/s Jevtana – Average Treatment Cycles in Complete Therapy (By Number)

- Figure 7-5: Provenge v/s Jevtana – Price Analysis (US\$/Unit), 2018
- Figure 7-6: Provenge v/s Jevtana – Price Analysis (US\$/Infusion), 2018
- Figure 7-7: Provenge v/s Jevtana – Average Treatment Cost Analysis (US\$), 2018
- Figure 7-8: Provenge v/s Zytiga – Median Progression Free Survival (Months)
- Figure 7-9: Provenge v/s Zytiga – Therapy Cost Analysis (US\$), 2018
- Figure 8-1: Global – Rocapuldencel-T Market Opportunity Analysis by Epidemiology of Renal Cell Carcinoma (Number of patients), 2018
- Figure 8-2: India – Average Lung Cancer Prevalence per Year
- Figure 8-3: India – Lung Cancer Prevalence by Stage (%), 2018
- Figure 8-4: India – Apceden Market Opportunity by Epidemiology of Lung Cancer (Number of Patients), 2014-2018
- Figure 8-5: India – Apceden Market Opportunity by Epidemiology of Ovarian Cancer (Number of Patients), 2014-2018
- Figure 8-6: India – Apceden Market Opportunity by Epidemiology of Colorectal Cancer (Number of Patients), 2014-2018
- Figure 8-7: India – Apceden Market Opportunity by Epidemiology of Prostate Cancer (Number of Patients), 2014-2018
- Figure 8-8: South Korea – Renal Cell Carcinoma Population by Stage of Cancer, (%), 2018
- Figure 8-9: South Korea – CreaVax RCC Market Opportunity by Renal Cancer Epidemiology (Number of Patients), 2014-2018
- Figure 8-10: South Korea – Renal Cell Carcinoma Prevalence in Male Population by Number, 2014-2018
- Figure 8-11: South Korea - Renal Cell Carcinoma Prevalence in Female Population by Number, 2014-2018
- Figure 8-12: South Korea – Renal Cancer Prevalence by Gender, 2018
- Figure 8-13: Japan – Epidemiology of Cancer by Gender (%), 2018
- Figure 8-14: Japan – Epidemiology of Cancer (Number of Patients), 2018
- Figure 8-15: Japan – Vaccell Market Opportunity by Epidemiology of Pancreatic Cancer by Gender (%), 2018
- Figure 8-16: Japan – Vaccell market Opportunity by Epidemiology of Pancreatic Cancer (Number of Patients), 2018
- Figure 8-17: Japan – Vaccell Market Opportunity by Epidemiology of Gall Bladder & Biliary Cancer by Gender (%), 2018
- Figure 8-18: Japan – Vaccell Market Opportunity by Epidemiology of Gall Bladder & Biliary Cancer (Number of Patients), 2018
- Figure 8 19: Japan – Vaccell Potential Patient Base by New Incidences, 2018
- Figure 10-1: Global - Scope of Dendritic Cell Cancer Therapy Market by Ongoing Researches

Figure 10-2: Global – Scope of Dendritic Cell Cancer Therapy Market by Approved Advanced Therapies

Figure 10-3: Global – Scope of Dendritic Cell Vaccine Cancer Therapy Market by Later Phase Clinical Trials

Figure 10-4: Global – Number of Advanced Cancer Therapy Research Studies Funded by Non-Profit Organization

Figure 12-1: Factors Favoring Global Dendritic Cell Cancer Vaccine Market

Figure 13-1: Global – Dendritic Cell Cancer Vaccine Market Opportunity by Prevalence of Cancer (%)

Figure 14-1: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Phase (%), 2018 till 2024

Figure 14-2: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 14-3: Global Dendritic Cell Cancer Vaccines Suspended in Clinical Pipeline by Phase (%), 2018 till 2024

Figure 14-4: Global Dendritic Cell Cancer Vaccines Suspended in Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 14-5: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Region/Country (%), 2018 till 2024

Figure 14-6: Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Company (%), 2018 till 2024

Figure 16-1: Argos Therapeutics- Clinical Pipeline

Figure 16-2: Bellicum Pharmaceuticals Clinical Pipeline

Figure 16-3: DCPrime Clinical Pipeline

Figure 16-4: ImmunoCellular Therapeutics Clinical Pipeline

Figure 16-5: Immunicum Clinical Pipeline

Figure 16-6: Medigene Clinical Pipeline

Figure 16-7: Northwest Biotherapeutics Clinical Pipeline

Figure 16-8: SOTIO Clinical Pipeline

I would like to order

Product name: Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024

Product link: <https://marketpublishers.com/r/GAD5A8EA37EEN.html>

Price: US\$ 2,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GAD5A8EA37EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970